Form 4: Director Calder Receives Zevra Therapeutics Stock Options

Douglas W. Calder, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options as compensation for his board service.

Summary

• Douglas W. Calder, a Director of Zevra Therapeutics, Inc., received a grant of 30,000 stock options on June 4, 2026.
• These options have an exercise price of $11.17 per share, which was the closing price of Zevra's common stock on the grant date.
• The options are part of the compensation for Mr. Calder's service on the company's board of directors, under the non-employee director compensation policy.
• Vesting of the options is scheduled for 100% on the earlier of the first anniversary of the grant date, one day before the first annual stockholders meeting after the grant, or immediately prior to a change in control of the issuer, provided Mr. Calder remains in service.
• The options have an expiration date of June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details standard director compensation through stock options rather than significant financial performance or strategic shifts.

Positives

• Director compensation aligns with board service, indicating a commitment to retaining experienced leadership.
• Stock options provide a direct incentive for the director to contribute to the company's long-term value creation.
• The exercise price being set at the closing price on the grant date suggests a fair market valuation at the time of the award.

Negatives

• The filing does not contain any negative information.

Risks

• The value of the stock options is subject to market fluctuations and the company's future stock performance.
• Vesting is contingent on continued service, meaning the director could forfeit the options if they leave the board before the vesting date.
• A change in control of the issuer could trigger immediate vesting, potentially impacting the company's strategic flexibility.

Future Outlook

The future outlook for the stock options is dependent on Zevra Therapeutics' stock performance and the director's continued service. The options are exercisable up to June 3, 2036, with vesting conditions tied to anniversaries, stockholder meetings, or a change in control.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to align executive and board interests with shareholder value and to attract and retain talent in a competitive industry.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Douglas W. Calder is a related party transaction, as it involves compensation for services rendered by an insider.

Stakeholder Impact

• Shareholders: The issuance of stock options dilutes ownership slightly but aligns director incentives with long-term shareholder value.
• Employees: This filing does not directly impact employees, but successful company performance driven by board oversight could benefit them.
• Management: The filing is a standard disclosure related to board compensation, not a direct management action.

Next Steps

• Douglas W. Calder will continue to serve as a Director for Zevra Therapeutics, Inc.
• The stock options will vest according to the schedule outlined in the filing.
• The company may experience a change in control, which would trigger immediate vesting of the options.

Key Dates

Keywords

Zevra Therapeutics, ZVRA, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Equity Award